NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Forecast, Price & News $0.98 +0.02 (+2.08%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.96▼$1.0150-Day Range$0.96▼$1.7952-Week Range$0.85▼$8.87Volume1.95 million shsAverage Volume4.54 million shsMarket Capitalization$104.85 millionP/E RatioN/ADividend YieldN/APrice Target$10.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Esperion Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside1,009.7% Upside$10.88 Price TargetShort InterestBearish15.52% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment-0.14Based on 7 Articles This WeekInsider TradingSelling Shares$1,438 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.98) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector670th out of 972 stocksPharmaceutical Preparations Industry316th out of 449 stocks 3.3 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.88, Esperion Therapeutics has a forecasted upside of 1,009.7% from its current price of $0.98.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.52% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Esperion Therapeutics has recently increased by 8.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 1.0 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,438.00 in company stock.Percentage Held by InsidersOnly 0.60% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions69.76% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($1.98) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Esperion Therapeutics (NASDAQ:ESPR) StockEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comZacks Research Weighs in on Esperion Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:ESPR)September 27, 2023 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Stock Passes Below 200 Day Moving Average of $1.51October 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 22, 2023 | seekingalpha.comEsperion Therapeutics Chief Commercial Officer discloses sale of 742 sharesSeptember 12, 2023 | finance.yahoo.comAmerican College of Cardiology Program to Increase Cholesterol ScreeningsSeptember 1, 2023 | msn.comShould I load up on Esperion Therapeutics shares under $2?August 31, 2023 | finance.yahoo.comWhy Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?August 29, 2023 | msn.comEsperion Therapeutics: Speculative Buy, Playing The $300 Million Milestone LitigationOctober 1, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 28, 2023 | msn.comWhy Is Esperion Therapeutics Stock Trading Higher Today?August 28, 2023 | finance.yahoo.comEsperion to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 26, 2023 | finance.yahoo.comEsperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023August 11, 2023 | finance.yahoo.comTwo CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023August 9, 2023 | finanznachrichten.deEsperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)August 6, 2023 | finance.yahoo.comWith 77% ownership, Esperion Therapeutics, Inc. (NASDAQ:ESPR) boasts of strong institutional backingAugust 3, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Esperion TherapeuticsAugust 2, 2023 | msn.comNeedham Maintains Esperion Therapeutics (ESPR) Buy RecommendationAugust 2, 2023 | finance.yahoo.comEsperion (ESPR) Q2 Earnings Top, Stock Up on Strong RevenuesAugust 1, 2023 | seekingalpha.comEsperion Therapeutics Q2 2023 Earnings PreviewAugust 1, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Esperion (ESPR)August 1, 2023 | markets.businessinsider.comEsperion (ESPR) Gets a Buy from JMP SecuritiesJuly 24, 2023 | finance.yahoo.comEsperion to Participate in BTIG Virtual Biotechnology Conference 2023July 17, 2023 | finance.yahoo.comEsperion to Report Second Quarter 2023 Financial Results on August 1July 7, 2023 | finance.yahoo.comEsperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023June 28, 2023 | finance.yahoo.comEsperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) TabletJune 26, 2023 | markets.businessinsider.comAnalyst Expectations for Esperion Therapeutics's FutureJune 26, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Esperion (ESPR)See More Headlines Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Company Calendar Last Earnings8/01/2023Today10/01/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees199Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.88 High Stock Price Forecast$22.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+1,009.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-233,660,000.00 Net Margins-252.82% Pretax Margin-252.82% Return on EquityN/A Return on Assets-84.89% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio1.74 Sales & Book Value Annual Sales$75.47 million Price / Sales1.39 Cash FlowN/A Price / Cash FlowN/A Book Value($4.39) per share Price / Book-0.22Miscellaneous Outstanding Shares106,990,000Free Float106,352,000Market Cap$104.85 million OptionableOptionable Beta0.13 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Sheldon L. Koenig (Age 57)Pres, CEO & Director Comp: $1.2MMr. Benjamin O. Looker (Age 41)Gen. Counsel Comp: $550.35kDr. JoAnne Micale Foody FACC (Age 57)M.D., Chief Medical Officer Comp: $771.19kMr. Benjamin Halladay M.B.A. (Age 37)Chief Financial Officer Mr. Glenn P. Brame (Age 65)Chief Technical Operations Officer Tiffany Aldrich M.B.A.Associate Director of Corp. CommunicationsMs. Betty Jean SwartzChief Strategy OfficerMr. Eric J. Warren R.Ph. (Age 51)Chief Commercial Officer More ExecutivesKey CompetitorsGreenwich LifeSciencesNASDAQ:GLSIOrganigramNASDAQ:OGINektar TherapeuticsNASDAQ:NKTRGalectin TherapeuticsNASDAQ:GALTProQR TherapeuticsNASDAQ:PRQRView All CompetitorsInsiders & InstitutionsBarclays PLCSold 56,779 shares on 9/21/2023Ownership: 0.097%Eric WarrenSold 742 sharesTotal: $927.50 ($1.25/share)Eric WarrenSold 243 sharesTotal: $342.63 ($1.41/share)Citadel Advisors LLCSold 49,600 shares on 8/15/2023Ownership: 0.000%Stifel Financial CorpBought 52,043 shares on 8/15/2023Ownership: 0.099%View All Insider TransactionsView All Institutional Transactions ESPR Stock - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ESPR shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price forecast for 2023? 9 Wall Street analysts have issued twelve-month target prices for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $4.00 to $22.00. On average, they anticipate the company's stock price to reach $10.88 in the next twelve months. This suggests a possible upside of 1,009.7% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2023? Esperion Therapeutics' stock was trading at $6.23 at the start of the year. Since then, ESPR shares have decreased by 84.3% and is now trading at $0.98. View the best growth stocks for 2023 here. Are investors shorting Esperion Therapeutics? Esperion Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 16,460,000 shares, an increase of 8.4% from the August 31st total of 15,180,000 shares. Based on an average daily trading volume, of 3,500,000 shares, the short-interest ratio is presently 4.7 days. Approximately 15.5% of the company's stock are short sold. View Esperion Therapeutics' Short Interest. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.15. The biopharmaceutical company earned $25.79 million during the quarter, compared to the consensus estimate of $24.64 million. The company's revenue was up 36.9% on a year-over-year basis. During the same period last year, the firm posted ($1.05) earnings per share. What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $0.98. How much money does Esperion Therapeutics make? Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $104.85 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. How many employees does Esperion Therapeutics have? The company employs 199 workers across the globe. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com. This page (NASDAQ:ESPR) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.